Immunotherapy Drugs Market Size, Patient Volume, Treatment Adoption Rates, Pricing Analysis, Regulatory Landscape, Clinical Trial Trends, Market Share, and Demand Forecast

Revenue, 2025

USD 318.83 Bn

Forecast Year, 2035

USD 1,607.94 Bn

CAGR, 2026 - 2035

17.56%

Report Coverage

Global

What is the Immunotherapy Drugs Market Size?

The global immunotherapy drugs market size was estimated at USD 318.83 billion in 2025 and is predicted to increase from USD 376.22 billion in 2026 to approximately USD 1,607.94 billion by 2035, expanding at a CAGR of 17.56% from 2026 to 2035.

Immunotherapy Drugs Market Key Takeaway

• North America dominated the global market with the largest market share of 46% in 2025.
• By indication type, the cancer segment held the highest market share of 92% in 2025.
• By drug type, the monoclonal antibodies segment captured the biggest market share of 77% in 2025.

What are Immunotherapy Drugs?

Immunotherapy is a type of cancer treatment that helps the immune system of the human body find and attack cancer cells. It uses potential substances made by the human body or in the laboratory. This treatment aims to stimulate or boost the immune system to make it capable of working better against cancer. It also adds laboratory-produced substances that act like natural parts of the immune system. Leading companies in the immunotherapy drugs market like AstraZeneca, Merck, Novartis, EMD Serono, Regeneron/Sanofi, Bristol-Myers Squibb, Kite, a Gilead company, and many others have launched immunotherapy drugs that are crucial in saving the lives of cancer patients globally.

How does AI impact the Immunotherapy Drugs Market?

AI plays a significant role in the prevention and early detection of cancer, which are the most powerful weapons against cancer. AI helps in predicting the incidence of pancreatic cancer, which is more difficult and expensive to screen for compared to other cancers. A trained AI model helps to scan imaging like MRIs to identify tumor-like structures in cancer patients. It helps oncologists and radiologists in a deeper examination of these affected areas. AI has a crucial impact on the development of treatment plans and precision medicine that further expand the immunotherapy drugs market. AI streamlines these processes and enables efficient drug discovery and development. Research has proven that AI enhances the speed and precision of drug target identification.

Market Outlook

• Industry Growth Overview: The immunotherapy drugs market is revolutionizing due to one of the most exciting aspects of immunotherapy, which is its potential for personalized medicine. Immunotherapy can be tailored based on the specific characteristics of each patient's cancer. Researchers are exploring the potential of combination therapies by combining immunotherapy with other treatment modalities to enhance its efficacy.
• Sustainability Trends: The ecological impact in drug discovery is prioritized to integrate sustainable concepts and adopt holistic benefit-risk assessments by the pharmaceutical industry. The sustainable concepts include environmental risk assessment early in the drug discovery process to mitigate environmental impact. Furthermore, the use of green chemistry principles such as bioconversions, environmental factors, and innovative methodologies plays an important role in reducing the environmental footprint of drug discovery and synthetic chemistry.
• Startup Ecosystem: Early-stage biotechnology startups that offer strong data, a potential management team, and a product targeting unmet needs are attracting investments. The presence of multiple companies creates opportunities to collaborate, access specialised service providers, share knowledge, and attract and retain talent. The startups are securing significant funding to meet the larger capital needs for process scaling.
• Global Expansion: Cancer remains an important area for continued investment in early diagnosis and screening, novel treatment modalities with improved clinical benefits, and access to care. The productivity of oncology clinical development has improved, while the oncology sector continues to see novel medicine launches. Cancer patient access to novel oncology modalities such as antibody drug conjugates, cell and gene therapies, and multispecific antibodies is expanding globally.

Immunotherapy Drugs Market Growth Factors

The rising prevalence of chronic diseases, rising healthcare expenditure, and growing adoption of the targeted therapy among the population are the major factors that propels the growth of the global immunotherapy drugs market. The growing popularity of the biosimilars owing to the approvals received by certain biosimilar drugs from the authorities like FDA and EMA is expected to be an important driving factor in the forthcoming years. The growing investments in the research and development by the biotechnology and pharmaceutical companies, rising number of research labs, and growing research collaborations by the key market players are the several crucial factors that are expected to have a significant impact on the market growth during the forecast period. The rapidly growing biopharmaceutical industry owing to the rising government support and rising corporate investments will augment the growth of the immunotherapy drugs market. Furthermore, the rising awareness regarding the benefits of the immunotherapy drugs over the traditional treatment procedures is significantly spurring the demand for the immunotherapy drugs.

Traditional therapies were expensive and were inefficient in treating the diseases. For instance, the chemotherapy used for the treatment of cancer, was very toxic. It involved the risks of organ failure, reoccurrence of cancer, and various other side-effects, which may cost the life of the patient even after receiving the treatment. The immunotherapy has low side-effects can are free from the risks that were associated with the traditional chemotherapy. This has significantly driven the demand for the immunotherapy drugs across the globe.

Market Trends

Advances in Cancer Immunotherapy: These innovations in 2025 are related to immune checkpoint inhibitors, bispecific antibodies, antibody drug conjugates, and cellular therapies. Several clinical trials in cancer immunotherapy are proving the promising potential and outcomes of CAR T cell therapy and antibody drug conjugates. The immunotherapy drugs market is evolving due to the immense role of these medications in cancer treatment.

Potential of Immune Checkpoint Inhibitors (ICIs): These immunotherapy drugs block the immune system and stop uncontrolled growth. Some of these drugs were approved for patients who are suffering from recurrent or metastatic squamous cell carcinoma of the anal canal, which is the most common form of anal cancer. Certain clinical trials showed a lower risk of disease recurrence for head and neck squamous cell carcinoma if patients receive ICIs with standard therapy.

Precision Medicine: Advances in genomic technologies like biomarker analyses and next-generation sequencing (NGS) enabled the precise identification of actionable targets for prevention and treatment strategies. A deep learning AI tool was designed to detect characteristics of homologous recombination deficiency in tumors using standard biopsy slides. This model helps identify patients who may benefit from targeted treatments such as platinum-based chemotherapy and PARP inhibitors.

Market Scope

Market Dynamics

Driver

What are the Trends Shaping the Future of the Immunotherapy Drugs Market?

The renewed business momentum and breakthrough innovations reshaped the global pharmaceutical and healthcare sectors. The expansion of the private market and growing healthcare system capacity challenges have driven these developments across the globe. Moreover, the evolving stakeholder engagement landscape is also boosting the market's expansion.

Restraint

What are the Numerous Health Challenges Facing the Immunotherapy Drugs Market?

The medical field needs to address various health challenges due to emerging medical needs. Research studies imply that there are around 6,500 therapy-resistant, life-threatening, incurable, and neglected diseases lacking regulatory-approved therapies. It should also navigate complex factors, like geopolitics, economic factors, and pharmaceutical profit motives. They ensure ethical decision-making in shaping healthcare missions.

Opportunity

What are the Opportunities and Advances in Immunotherapy?

Immunotherapies are considered at the cutting-edge of therapeutic research. They offer some of the most advanced treatments for cancer and other diseases. These treatments introduce several different approaches, including adoptive cell therapies, immune checkpoint inhibitors, cancer vaccines, oncolytic virus therapy, and immune system modulators.

Segment Insights

Drug Type Insights

The monoclonal antibodies segment dominated the global immunotherapy market in 2025. The monoclonal antibodies are considered to be the most effective type of immunotherapy that cures various chronic diseases. The higher safety of the immunotherapy owing to the lower toxicity results in minimal or no side effects. The increasing popularity of the monoclonal antibodies due to its low side-effects is fueling the demand for the monoclonal antibodies. The government authorities like FDA and EMA are playing a crucial role in the rising adoption of the monoclonal antibodies. In 2017, the FDA and EMA collectively approved 73 monoclonal antibodies.

The vaccines segment is estimated to be the fastest-growing segment during the forecast period. The rising burden of various infections and diseases is fueling the investments on the development of vaccines. For instance, in 2020, the rapid spread of the COVID-19 disease have positively impacted the growth of this segment as the top pharmaceutical companies were engaged in the development of immunotherapy-based vaccines and drugs.

Therapeutic Area Insights

Cancer was the most dominant therapeutic area in 2025. This is attributed to the increased prevalence of cancer across the globe. As per the GLOBOCAN, a report published by the International Agency for Research on Cancer, around 19.3 million new cancer cases and 10 million cancer deaths were reported across the globe, in 2020. The new cancer cases are expected to rise by 47% from 2020 to 2040, globally. Therefore, it is estimated that around 28.4 million new cancer cases will be recorded in 2040 across the globe. The most prominent type of cancer includes lungs cancer, prostate cancer, breast cancer, and colorectal cancer. The increased demand for the immunotherapy drugs to treat cancer has fostered the growth of this segment and the rapidly growing cases of cancer are anticipated to sustain the dominance of this segment throughout the forecast period. Moreover, the immunotherapy drugs targets the cancer cells in the body and treats I without harming the normal cells, which leads to low or no side-effects. These advantages of the new immunotherapy drugs over the traditional chemotherapy are compelling the patients to adopt the immunotherapy drugs that foster the growth of this segment, globally.

The autoimmune and inflammatory diseases segment is expected to grow at the fastest rate in the market during the forecast period due to the emergence of immunotherapy as a promising approach to treating inflammatory and autoimmune disorders. These conditions include lupus, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, and psoriasis. Immunotherapies, including biologic agents, immune checkpoint inhibitors, and monoclonal antibodies, have revolutionized the management of these disorders.

Regional Insights

North America Dominated the Immunotherapy Market in 2025

North America dominated the global immunotherapy market in 2025. This can be attributed to the increased prevalence of the chronic diseases in the major market like US. Around half of the US population is suffering from one or more chronic diseases. This has resulted in the increased healthcare expenditure. Moreover, as per the American Cancer Society, over 1.8 million new cancer cases and 606,520 deaths were reported in the US in 2020. The colorectal cancer, lungs cancer, prostate cancer, and breast cancer are the most prominent types of cancers in US. The increased awareness among the US population regarding the immunotherapy drugs coupled with the increased healthcare expenditure and enhanced access to the healthcare facilities has augmented the market growth in this region. The presence of developed healthcare infrastructure and presence of several top biopharmaceutical companies has significantly contributed towards the market growth.

U.S. Immunotherapy Drugs Market Size and Growth 2026 to 2035

The U.S. immunotherapy drugs market size accounted for USD 102.66 billion in 2025 and is expected to be worth around USD 528.75 billion by 2035, growing at a CAGR of 17.81% from 2026 to 2035.

U.S. Market Trends

The use of AI in the discovery of biomarkers and patient selection for improved efficacy of immunotherapeutic is quickly becoming a reality in the U.S. landscape. CAR-Ts are being produced as they are becoming more widely available. The focus of regulatory authorities is also shifting to optimisation of the doses of these immune checkpoint blocking drugs, and the country's robust healthcare system continues to be a driver of the highest uptake of immunotherapy drugs.

Asia Pacific is estimated to be the most opportunistic market during the forecast period owing to the rising prevalence of target diseases among the population. According to the International Journal of General Medicine 2018, the mortality from the chronic diseases is rapidly rising in the low and middle income countries, accounting for around 75% of the global deaths from the chronic diseases. The alarming rise in the number of chronic diseases and deaths due to it is expected to spur the demand for the immunotherapy drugs in this region. Moreover, the rising government expenditure on the development of healthcare infrastructure and improving the access to the healthcare facilities is significantly fostering the growth of the immunotherapy drugs market in Asia Pacific.

China Market Trends

Cancer rates are rising in China, and health care has become increasingly upgraded, with a rapid rise in the use of immunotherapy drugs. The research effort and clinical trials are sufficient in the country to study tumour immunology. The demand for monoclonal antibodies and next-generation therapy is growing, and with it, there is growing interest in the biotechnology industry for studies on oncolytic virus immunotherapy.

What Are the Driving Factors of The Immunotherapy Drugs Market in Europe?

Europe is expected to grow at a significant CAGR during the forecast period. The European market is a proven one for immunotherapy products and also has a significant cancer burden with high regulatory activity to facilitate the uptake of biosimilars. Technological advances in treatment and good reimbursement policies, combined with the use of these therapies in specialist cancer treatment centers, are also contributing to an increasing use of these treatments in major European countries.

Germany Market Trends

Companies such as BioNTech SE and Merck KGaA are making big investments in the development of cell-based immunotherapy to improve Germany's position in the market. The administration of drugs is also transitioning to drugs that are injected under the skin, enabling the drugs to reach the market quickly. The reimbursement support and the growing demand for oncology have kept PD-1 and PD-L1 inhibitors strong.

What Are the Driving Factors of The Immunotherapy Drugs Market in Latin America?

Latin America is expected to grow at a significant CAGR during the forecast period. The growing consciousness and the growing patient population in the Latin America (LA) region for targeted immunotherapy are the driving forces of the market. The growing awareness and the increasing number of patients available for targeted immunotherapy treatment in the Latin America region are driving the market.

Brazil Market Trends

With the emergence of new therapies in the form of immunotherapies, the use of monoclonal antibodies has become more and more popular in Brazil. Chronic diseases and cancers are increasing, and so is the need for state-of-the-art cancer treatments. Further, access to innovative immunotherapy drugs and cancer treatment services is being supported by collaborative efforts through strategic partnerships, outsourcing, and investment in the healthcare sector.

Immunotherapy Drugs Market Companies

• F. Hoffmann-La Roche AG
• GlaxoSmithKline plc.
• AbbVie, Inc.
• Amgen, Inc.
• Merck & Co., Inc.
• Alligator Bioscience
• UbiVac
• Bristol-Myers Squibb
• Novartis International AG
• AstraZeneca plc

Recent Developments

• In April 2026, Merck announced that it has turned its wonder drug into a blockbuster. This pharmaceutical giant has established a fortress of patents, lobbied to guard its revenue kingpin Keytruda, and traded in secrecy. It has also priced out cancer patients globally. (Source: https://www.icij.org)
• In January 2026, Biocon announced its plan to launch Keytruda, Opdivo, and Herceptin Hylecta among three oncology biosimilars at the JP Morgan Annual Healthcare Conference in San Francisco. This pipeline carries PD-1 therapies, which have emerged as the preferred immunotherapy regimen for multiple cancer indications. (Source: https://pharma.economictimes.indiatimes.com)
• In January 2026, Zydus Lifesciences launched the world's first nivolumab biosimilar, Tishtha, in India at nearly a fourth of the price of BMS's Opdivo, significantly enhancing access to important cancer immunotherapy on January 22. (Source: https://www.moneycontrol.com)
• In August 2025, Intas Pharmaceuticals introduced HETRONIFLY™ (Serplulimab), the first globally approved PD-1 inhibitor for Extensive-Stage Small Cell Lung Cancer in India, following a European launch and a licensing agreement with Shanghai Henlius Biotech. (Source: https://www.prnewswire.com)
• In July 2019, Allergan Plc and Amgen, Inc. KANJINTITM, a biosimilar to Herceptin, and MVASi, a biosimilar to Avastin in the US. MVASI was the first cancer biosimilar that got the FDA approval.
• In May 2020, VinsBioproducts Ltd. collaborated with the University of Hyderabad and the CSIR Center for Cellular and Molecular Biology, in India to develop immunotherapy treatment for COVID-19.
• The various developmental strategies like partnerships, acquisitions, mergers, collaborations, and new product launches with latest and innovative features fosters market growth and offers lucrative growth opportunities to the market players.

Market Segmentation

By Drug Type

• Monoclonal Antibodies
• Vaccines
• Interleukins
• Interferons Alpha & Beta
• Others

By Therapeutic Area

• Cancer
• Infectious Diseases
• Autoimmune & Inflammatory Diseases
• Others

By Region

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
• MEA
• Rest of the World